GlassScriptPhysician profile
Lacy Kusy
NPI 1700249596
$5,379.09
in general payments reported to CMS, 2019-2025
24 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $325 · 2022: $1,329 · 2023: $1,616 · 2024: $1,844 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,725.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,019.83 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $976.17 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Radius Health, INC. | $477.31 | 2021-2024 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $416.03 | 2021-2024 | |
| Amgen INC. | $322.44 | 2022-2024 | Prolia, Evenity, Repatha |
| Xeris Pharmaceuticals, INC. | $321.29 | 2021-2024 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $250.36 | 2021-2023 | |
| Dexcom, INC. | $215.21 | 2022-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.64 | 2021-2024 | Jardiance |
| Boston Scientific Corporation | $181.14 | 2021-2025 | Watchman Flx, Watchman |
| Abbvie INC. | $164.03 | 2021-2024 | |
| Medtronic, INC. | $158.52 | 2022-2025 | Minimed 780g |
| Averitas Pharma INC. | $155.54 | 2023-2024 | Qutenza |
| Corcept Therapeutics | $118.59 | 2023-2025 | Korlym |
| Beta Bionics, INC. | $101.72 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $92.51 | 2022-2023 | Omnipod |
| Tandem Diabetes Care, INC. | $57.81 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $40.07 | 2022-2024 | Freestyle Libre 3 |
| Nevro Corp. | $30.79 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.27 | 2023 | |
| Ibsa Pharma INC. | $21.57 | 2024 | Licart, Tirosint |
| Astrazeneca Pharmaceuticals LP | $15.92 | 2021 | |
| Grt US Holding, INC. | $13.20 | 2022 | |
| Merck Sharp & Dohme LLC | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacy Kusy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.